Brokerages forecast that Teladoc Health, Inc. (NYSE:TDOC) will announce earnings per share of ($0.59) for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have provided estimates for Teladoc Health’s earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.92). Teladoc Health reported earnings per share of ($0.40) in the same quarter last year, which would indicate a negative year-over-year growth rate of 47.5%. The company is scheduled to report its next earnings report on Wednesday, May 5th.
On average, analysts expect that Teladoc Health will report full-year earnings of ($2.06) per share for the current fiscal year, with EPS estimates ranging from ($3.32) to ($0.29). For the next fiscal year, analysts forecast that the company will report earnings of ($0.90) per share, with EPS estimates ranging from ($3.10) to $1.15. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Teladoc Health.
Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 24th. The health services provider reported ($3.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($2.82). Teladoc Health had a negative return on equity of 6.15% and a negative net margin of 12.71%.
Several equities research analysts have weighed in on the company. Evercore ISI began coverage on Teladoc Health in a research report on Tuesday, December 22nd. They issued an “in-line” rating and a $215.00 target price on the stock. Jefferies Financial Group cut their price target on Teladoc Health from $264.00 to $248.00 and set a “hold” rating on the stock in a report on Wednesday, March 3rd. Oppenheimer increased their price objective on Teladoc Health from $250.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, March 3rd. BTIG Research lifted their price objective on shares of Teladoc Health from $260.00 to $330.00 and gave the company a “buy” rating in a research note on Tuesday, January 26th. Finally, Credit Suisse Group boosted their price target on shares of Teladoc Health from $296.00 to $300.00 and gave the stock an “outperform” rating in a research report on Thursday, March 4th. Fourteen analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $241.38.
In other news, insider Arnnon Geshuri sold 1,750 shares of Teladoc Health stock in a transaction dated Tuesday, February 16th. The shares were sold at an average price of $298.26, for a total transaction of $521,955.00. Following the completion of the transaction, the insider now directly owns 102,569 shares in the company, valued at $30,592,229.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Adam C. Vandervoort sold 2,610 shares of the firm’s stock in a transaction that occurred on Wednesday, February 3rd. The shares were sold at an average price of $269.85, for a total value of $704,308.50. Insiders have sold 674,374 shares of company stock worth $135,744,738 in the last ninety days. Insiders own 3.42% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. General Catalyst Group Management LLC purchased a new position in shares of Teladoc Health in the 4th quarter worth approximately $1,610,161,000. Aequim Alternative Investments LP increased its stake in shares of Teladoc Health by 33,044.2% during the 4th quarter. Aequim Alternative Investments LP now owns 3,447,000 shares of the health services provider’s stock worth $1,071,000 after purchasing an additional 3,436,600 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Teladoc Health by 148.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,221,549 shares of the health services provider’s stock worth $644,181,000 after purchasing an additional 1,927,001 shares during the period. Nikko Asset Management Americas Inc. grew its holdings in Teladoc Health by 173.4% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 2,824,067 shares of the health services provider’s stock valued at $564,700,000 after buying an additional 1,791,008 shares in the last quarter. Finally, Baillie Gifford & Co. raised its holdings in shares of Teladoc Health by 16.0% in the 4th quarter. Baillie Gifford & Co. now owns 7,238,667 shares of the health services provider’s stock valued at $1,447,444,000 after acquiring an additional 996,628 shares in the last quarter. 51.77% of the stock is owned by institutional investors and hedge funds.
Teladoc Health stock traded up $0.74 during midday trading on Monday, hitting $182.00. The stock had a trading volume of 68,829 shares, compared to its average volume of 3,574,662. The stock has a market cap of $27.79 billion, a P/E ratio of -126.76 and a beta of 0.30. The business has a fifty day moving average price of $203.79 and a 200 day moving average price of $216.41. The company has a current ratio of 6.52, a quick ratio of 6.47 and a debt-to-equity ratio of 0.43. Teladoc Health has a 12 month low of $147.71 and a 12 month high of $308.00.
About Teladoc Health
Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.
Read More: What are catch-up contributions?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.